BAVARIAN NORDICBB

BAVARIAN NORDIC

23.250EURD
−0.160−0.68%
At close at Feb 21, 23:13 GMT
EUR
No trades
See on Supercharts

BV3 fundamentals

Key facts

Market capitalization‪1.84 B‬EUR
Founded1992
Employees (FY)‪1.38 K‬
CEOPaul Chaplin
About

Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.

Ownership
‪‪78.65 M‬‬
Free Float shares
‪‪77.61 M‬‬ (98.67%)
Closely held shares
‪‪1.04 M‬‬ (1.33%)
Free Float shares
‪‪77.61 M‬‬ (98.67%)
Closely held shares
‪‪1.04 M‬‬ (1.33%)
Capital structure
Market cap
‪‪1.84 B‬‬
Debt
‪‪15.32 M‬‬
Cash & equivalents
‪‪250.84 M‬‬
Enterprise value
‪‪1.60 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪1.84 B‬‬
Price to earning ratio (P/E)
12.02x
Price to sales ratio (P/S)
2.25x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
12.02x
Price to sales ratio (P/S)
2.25x
Valuation ratios
‪0.00‬
‪0.80‬
‪1.60‬
‪2.40‬
‪3.20‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪5.00‬
‪10.00‬
‪15.00‬
‪20.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−40%‬
‪−20%‬
‪0%‬
‪20%‬
‪40%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−110.00 M‬‬
‪0.00‬
‪‪110.00 M‬‬
‪‪220.00 M‬‬
‪‪330.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪50.00 M‬‬
‪‪100.00 M‬‬
‪‪150.00 M‬‬
‪‪200.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪50.00 M‬‬
‪‪100.00 M‬‬
‪‪150.00 M‬‬
‪‪200.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Life-Saving Vaccines
By country
Period: 2023
United States
Canada
France
Germany
Other
Spain
Australia
Switzerland
Sweden
Chile

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪90.00 M‬‬
‪‪180.00 M‬‬
‪‪270.00 M‬‬
‪‪360.00 M‬‬
Actual
Estimate
Earnings
Next:Mar 5, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪−0.70‬
‪0.00‬
‪0.70‬
‪1.40‬
‪2.10‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

BV3 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−70.00 M‬‬
‪0.00‬
‪‪70.00 M‬‬
‪‪140.00 M‬‬
‪‪210.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪300.00 M‬‬
‪‪600.00 M‬‬
‪‪900.00 M‬‬
‪‪1.20 B‬‬
Assets
Liabilities